EyePoint Pharmaceuticals (STU:PV3) Other Long-Term Liabilities : €0.00 Mil (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is EyePoint Pharmaceuticals Other Long-Term Liabilities?

EyePoint Pharmaceuticals's other long-term liabilities for the quarter that ended in Dec. 2023 was €0.00 Mil.

EyePoint Pharmaceuticals's quarterly other long-term liabilities declined from Jun. 2023 (€0.00 Mil) to Sep. 2023 (€-0.00 Mil) but then increased from Sep. 2023 (€-0.00 Mil) to Dec. 2023 (€0.00 Mil).

EyePoint Pharmaceuticals's annual other long-term liabilities declined from Dec. 2021 (€2.08 Mil) to Dec. 2022 (€0.57 Mil) and declined from Dec. 2022 (€0.57 Mil) to Dec. 2023 (€0.00 Mil).

EyePoint Pharmaceuticals Other Long-Term Liabilities Historical Data

The historical data trend for EyePoint Pharmaceuticals's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals Other Long-Term Liabilities Chart

EyePoint Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long-Term Liabilities

Get a 7-Day Free Trial

EyePoint Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Long-Term Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

EyePoint Pharmaceuticals Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

EyePoint Pharmaceuticals Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

EyePoint Pharmaceuticals (STU:PV3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (STU:PV3) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

EYPT:USA PV3B:Germany

Address

480 Pleasant Street, Suite B300, Watertown, MA, USA, 02472

Website

https://www.eyepointpharma.com

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

EyePoint Pharmaceuticals (STU:PV3) Headlines

No Headlines